Molecular Diagnostics, Inc. Announces Director and Officer Resignation
Posted on: Friday, 2 September 2005, 18:00 CDT
Molecular Diagnostics, Inc. (OTCBB: MCDG.OB) announced today that Denis M. O'Donnell, M.D. voluntarily stepped down as a Director, Chief Executive Officer and President, indicating his desire to be fully supportive with the Molecular shareholder's efforts at restructuring the company. His resignation was accepted by the Board of Directors.
Dr. O'Donnell also said he will be available to consult with Molecular on any business or legal matters as needed.
About Molecular Diagnostics, Inc.
Molecular Diagnostics develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, gastrointestinal, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening system that can be integrated into existing medical models or at the point-of-care.
More information is available at: www.Molecular-Dx.com
Certain statements in this release are forward-looking. These statements are based on Molecular Diagnostics' current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate Molecular Diagnostics' expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by Molecular Diagnostics with the Securities and Exchange Commission. Actual results may differ materially from Molecular Diagnostic's current expectations depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2005 and June 30, 2005. Except as expressly required by law, Molecular Diagnostics undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Source: Business Wire
Related Articles
- Research and Markets: Biochip and Nanobiotechnology Expected to Make Significant Contribution to Growth of Molecular Diagnostics
- Molecular Diagnostics, Inc. Completes Convertible Note Financing
- Molecular Diagnostics, Inc. Receives Notice That Unauthorized Trading on Berlin-Bremen Stock Exchange Ceases
- Molecular Diagnostics, Inc. Demands Immediate End to Unauthorized Trading on Berlin-Bremen Stock Exchange
- Molecular Diagnostics, Inc. Dismisses Lawsuit
- Molecular Diagnostics, Inc. Announces Executive Changes
- Molecular Diagnostics, Inc. Files SEC 10-QSB Quarterly Report
- Molecular Diagnostics, Inc. Adds Leading Biomolecular Researcher to Its Ranks
- Molecular Diagnostics, Inc. Awarded Point-of-Care Cervical Screening Patent
- Molecular Diagnostics, Inc. Files 2002 Annual Report
 |
 |
User Comments (0)
RSS Feeds